Colorectal Carcinoma in Children and Adolescents - Case Reports and Literature Review

A B S T R A C T

Colorectal carcinoma (CRC) is extremely rare among pediatrics, particularly before puberty. It usually begins with nonspecific signs and symptoms, so the index of suspicion is low, consequently, the diagnosis may be delayed. Reports in the literature indicate that poor prognostic factors are more common in children than in adults, resulting in a worse outcome. Our objective is to report clinical profile, treatment and prognosis of CRC in children and adolescents admitted in our institution, and to perform a systematic review of reports in the bibliography.

Keywords

Colon carcinoma, child, adolescents

Introduction

Colorectal adenocarcinoma (CRC) is the third most common malignancy in the adult population, surpassed only by lung and breast cancers. However, only 1-4 % of all CRC occurs in patients younger than 25-30 years old, being extremely rare among children, particularly before puberty. However, it is the most common gastrointestinal primary malignancy after liver tumors according to the Surveillance, Epidemiology, and End Results (SEER) database [1, 2].

Initial signs and symptoms may be nonspecific. Available data showed that the most common symptom was abdominal pain (54%), change in bowel habits (38%), rectal bleeding (31%), weight loss (19.7%), nausea and vomiting (17%), and iron deficiency anemia (77%). In advanced disease there may be intestinal obstruction and perforation associated with a poor prognosis. The acute onset is more common in pediatrics (>20%) [1].

Because of the rarity of the pathology, these signs and symptoms are often underestimated or misunderstood as other more common childhood problems such as gastroenteritis, which may lead to a delay in diagnosis; the median time elapsing between the first symptoms and diagnosis was reportedly 3 months for patients younger than 20 years old, as opposed to 1 month for those over 20 [1, 3-4]. Furthermore, it has been hypothesized that the delay in diagnosis could partly explain the advanced stages in children [5]. CRC in children differs from adults mainly in higher incidence of aggressive histological features (poorly differentiated, signet-ring or mucinous adenocarcinoma subtypes), advanced stage, more microsatellite instability and worse survival rate [1].

Patients and Methods

We retrospectively analyzed all patients younger than 20 years old with diagnosis of CRC referred to Hospital de Pediatría Dr. J.P. Garrahan, Buenos Aires, Argentina between September 1987 and December 2020. A systematic review of the literature was performed using keywords and MeSH terms "Adolescent" AND/OR "Child" AND "Colorectal Neoplasms". Case reports were qualitatively assessed and analyzed according to predefined criteria: n >5 and younger than 30 years old.

Result / Case Reports

Fifteen patients younger than 20 years old (range 11-19) were admitted during the study period (Table 1). Ten were male and five were female. The median time of delay in diagnosis was 2.37 months (range 8 days-5 months). The most common symptoms were abdominal pain and weight loss; 5 patients reported acute surgical abdomen.

Table 1: Case reports.



Age

Sex

Predisposing factors

Signs & Symptoms

Delay

Location

Histology

Dukes stage

Survival

1

11y10m

M

Ulcerative colitis

Ulcerative colitis

Colonoscopy control

Sigmoid- Rectum

Mucinous

D

alive

2

15y4m

M

-

Gastrointestinal bleeding

 + weight loss

3m

Sigmoid- Rectum

Mucinous + Signet-ring cells

C

Dead (OS 19.9m)

3

15y7m

F

-

Diarrhea + weight loss

2m

Hepato-colic angle

Mucinous

D

Dead (OS 6.2m)

4

13y11m

M

NF1 -High grade glioma

Abdominal pain + gastrointestinal bleeding

1.5m

Sigmoid

Mucinous

D

Dead

5

14y10m

M

-

-

-

Colon

Mucinous + Signet-ring cells

D

Dead (OS 11.3m)

6

15y5m

M

-

Abdominal pain + rectal bleeding + diarrhea + weight loss

4m

Rectum

Mucinous

-

Dead (OS 5.3m)

7

14y7m

F

-

Abdominal pain + anemia + weight loss

5m

Sigmoid- Rectum

Poorly differentiated

D

Dead (OS 7.9m)

8

19y

M

High grade glioma / glioblastoma

Lower gastrointestinal bleeding

-

-

 

-

-

Dead

9

17y

F

Crohn's disease

Crohn's disease

Colonoscopy control

Rectum

Well -differentiated

A

Dead (OS 10.3m)

10

16y

F

-

Acute surgical abdomen (occlusion) + anemia

8d

Hepatic flexure

Moderately differentiated

C

Dead (OS 18.5m)

11

14y9m

F

-

Acute surgical abdomen (pain + vomiting)

11d

Cecum

Signet-ring cells

D

Dead (OS 5.8m)

12

11y9m

M

-

Abdominal pain + change in bowel habits

3m

Sigmoid

Mucinous + Signet-ring cells

-

Dead

13

12y3m

M

-

Acute surgical abdomen + abdominal pain

3 m

Sigmoid

Signet-ring cells

-

Dead (OS 1.7m)

14

14y8m

M

-

Abdominal pain + weight loss + intestinal obstruction

3 m

Transverse

Mucinous

C

Dead

15

14y

M

-

Abdominal pain + vomiting + change in bowel habits

1m

Hepatic flexure

Moderately differentiated

C

Alive

y: Years; m: Months; d: Days; M: Male; F: Female; NF1: Neurofibromatosis type 1; OS: Overall Survival.


Two patients had been previously diagnosed and treated for a high-grade glioma, one of them with Neurofibromatosis type 1. Other two patients had increased risk factors for developing CRC: One with Crohn's disease and one with ulcerative colitis.

Unfavorable histotypes were more frequent: mucinous adenocarcinoma was observed in 9 patients, 5 being signet ring cell carcinoma. Poorly differentiated and undifferentiated tumors (grades III and IV) were seen in 6 of the 15 patients. Rectosigmoid was the most common primary site (8 patients). Fourteen patients reported an advanced stage of the disease (Dukes stage III-IV); more than half had distant metastases, seen in 9 of the 15 patients. At the moment of this analysis only 2 patients were alive, thirteen died because of the disease. The 1-year progression-free survival was 28,5%. Median mortality time was 9.8 months. An important limitation for our series is the lack of adequate immunohistochemical and genetic analyses on our patients.

Literature Review

Twenty-six full-text articles were retrieved (Table 2). The youngest reported patient was a 9-month-old girl [6]. Most reports confirm that pediatrics have unfavorable histotypes, advanced stages and double rates of metastases than adults, as we observed in our series. The 5 years overall survival reported for children is between 10-48% vs 60-81% for adults [2, 5, 7-9]. In our series only two patients were alive at the time of this study. The risk factors with statistical significance identified were: aggressive histological features, advanced Dukes stages, metastasis, lymph node involvement, complete surgical resection, use of adjuvant chemotherapy [1, 3, 10-11].

The median delay in diagnosis reported is between 1 and 4.5 months, coincident with our series [5, 10-15]. This worse prognosis than in adults may be due to the aggressive behaviour and/or the delayed diagnosis resulting in an advanced stage of the disease, with a lower chance of complete resection, the mainstay of its treatment [5, 23, 27, 30].

Table 2: Systematic literature review of case reports.

Author

n

Age (y)

Family History of CRC or Genetic Syndromes

Pathology

Stage

Survival/ Comments

Mathey, 2021, Argentina

15

< 20 (r:11-19)

2 history of HGG (1 NF1)

1 Crohn

1 UC

Mucinous: 9

Signet-ring cells: 5

Poorly differentiated: 6

Dukes C/D: 14

M1: 9

2 pts alive

Cortez-Pinto, 2019, Portugal [29]

5

< 18 (r:9-17)



4/5 had family history of cancer in 2nd-degree relatives (2 CRC history) No MSI or MMRD

3/5 signet ring cells/mucinous histology





Khan SA, 2016, USA [7]

94

<30

(r:11-30)

Family history in 43% (vs. 26% in adults)

Poorly differentiated 37%

Signet-ring cells 13%

Advanced stages 76%



OS 5-y 40-48% (vs. 70-81%) compared with adults

Poles GC, 2015, USA [16]

918

(SEER)

<21

FAP 2.6% (p<0.001) compared with adults

Signet-ring cells 15.4%

Mucinous 17.5%

Poorly differentiated 30%

Stages III-IV 62% (vs. 37%)



Weber ML, 2016, German [17]

31

≤18

11 pts: 8 HNPCC - 1 FAP - 2 other





OS 100% vs 36-50% without Genetic Syndromes

6 pts developed other malignancies: 3 NHL-T, 3 Glioblastoma

Du F, 2015,

China [8]

19

10-20

MMRD in 2 of 9 pts analyzed

Signet-ring cells 37%

Mucinous 26%

Stages: III 52.6% y IV 26.3%. Nodes + 89%.

OS 5-y 23%

Rahman M, 2014, Bangladesh [18]

7

6-10

2 FAP

2 Signet-ring cells

5 Poorly differentiated

Dukes Stages: 4 pts D, 1 pt By 2 pts A (both with FAP)



Kaplan MA, 2013, Turkey [1]

76



<25

15 family history of CRC (21.7%)

5 (6.8%) APC





OS 16.3 m (r: 1-107 m).

Tay CH, 2012, Taiwan [19]

8

0-18

-



87.5% Dukes stages C/D

25% CEA high level.

Sultan I, 2010, Jordan, SEER [2]

159

4-20

10% APC

Mucinous 22%.

Signet-ring cells 18%.

Poorly differentiated / undifferentiated 31.9%.

Localized 19%

OS 5-y 40% vs 60% adults

Salas-Valverde S, 2009, Costa Rica [13]

11

7-17

2 APC, 1 Turner syndrome

Mucinous 64%



0 Dukes A and 2 Dukes B: alive

9 Dukes C/D: OS: < 17 m

Delay in diagnosis: 6 days -1 y (media: 3.9 m).

Ferrari A, 2008, Italy [9]

27

<30

3 pts MSI (1 family history of HNPCC) vs.

6 FAP + 5 HNPCC in adults



Stages III-IV 86% vs 40% in adults

Delay in diagnosis: 1-12 m.

PFS 5-y 18% and OS 5-y 23% vs. PFS 62.5% and OS 73% in adults.

Hill DA, 2007, USA

[3]

77

7-19

1 FAP, 6 juvenile polyps,

1 UC, 1 NF1,

 2 history of irradiation because of RMS.

3 pts 2nd malignancy

Mucinous 62%

Advanced stages 86%, M1 51%.

OS 10-y: 20.1%; EFS 10-y: 17.7%.

21% pts alive with medial survival of 12.2 y.

Kravarusic D, 2007, Israel [20]

7

2-18

-

4 Mucinous +/- Signet-ring cells



Delay in diagnosis 2-12m

3 pts alive



Durno C, 2005, Canada [21]

16

9-24

8/11 MSI

6/14 CMMRD

1 CMMRD: homozygous MLH-1 - brother (11y) with duodenal adenocarcinoma





7/16 developed 2nd malignancies

Chantada GL, 2005, Argentina [5]

21

10-30

3 family history of CRC



Pts <20 years old: Staged III and IV

11/14 died

OS 5-y 10% vs. 72% in adults

Delay in diagnosis: 2-24 m

Radhakrisshnan CN, 2003, England [22]

8

<16

-

Poorly differentiated 50%

All Dukes stage C

All died (1-12 m from diagnosis)

Vastyan AM, 2001, Hungary / UK [14]

7

<15

(r:9-15)

1: 2nd malignancy (Astrocytoma previous)

 1: later presented 2nd malignancy (AML)

5/7 aggressive histological

5 Dukes stage C

2 Dukes stage D

*1 case: metastasis in ovaries (Kruckenberg tumors)

6 pts died (6m-5y from diagnosis)

Delay in diagnosis: 1-12 m (media 4 m)

Datta RV, 2000, USA [11]/

 La Quardia MP, 1992, USA [10].

29

<21

7 family histories of CRC

1 HNPCC

1 FAP

1 UC

6/16 MSI

1 previous irradiation because of Wilms´ tumor

Signet-ring cells 45%. Poorly differentiated 24%.



76%: lymph node involvement

24 % metastasis.



Median delay in diagnosis: 2 m

OS 3-y: 24%.

Median OS: 16 m

If complete resection: median OS 33 m

Karnak I, 1999, Turkey [23]

20

<16

(r:7-16)

3 family histories of CRC

1 Bloom Syndrome

16/20 (80%) Mucinous



100% advanced stage (35% Dukes C, 65% Dukes D)

17/20 died

Delay in diagnosis: 2-15 days in Acute surgical abdomen; 1-24m in other clinical presentations.

Steinberg, 1988, USA [24]

9

10-20

1 Turcot syndrome

6 Poorly differentiated or Mucinous





5 pts delayed diagnosis (>3 m, median delay in diagnosis 11,6 m): 2 pts Dukes C and 3 pts Dukes D, median OS 4 m.

4 pts early diagnosis (median 20 days): 3 Dukes C and 1 Dukes D, median OS 24 m.

Andersson, 1976, Sweden [25]

6

< 15

-





2 pts Acute surgical abdomen

All died. Longest survival 3y9m

Chabalco, 1975, USA [26]

76

<20

1 family CRC

4 FAP- 3 UC - 1 colitis granulomatous

1: Mangioendothelioma

1: Astrocytoma previous (Turcot syndrome)

32% Mucinous.





Brown, 1992, South Africa [15]

7

10-15

-

5 Mucinous

4 Poorly differentiated

2 Signet-ring cells.



4 pts initial diagnosis: Acute surgical abdomen

Delay in diagnosis 4.5m (r:2-6 m).

Lamego CMB, 1989, Brazil [27]

11

6-15

1 FAP

8 pts Mucinous

7 pts stages III and IV.

5 pts metastasis

Delay in diagnosis: 2-360 days

Goldthorn JF, 1983, Taiwan [28]

7

11-20

3 pts with predisposition (FAP o UC)

1 Mucinous

3 pts Dukes stage D

5 pts died

Indini, 2017, Italy [12]

12

< 18

2 pts MMRD.

5 Poorly differentiated

4 Mucinous

2 pts Signet-ring cells

All stages II/IV

6 pts metastasis.

6 pts alive with survival of 51.7 m

6 pts disease progression

OS of 17 m (r:3-34 m)

Delay in diagnosis: 1-12 m

Pts: Patients; y: Years; m: Months; HGG: High Grade Glioma; FAP: Familial Adenomatous Polyposis; HNPCC: Hereditary Non-Polyposis Colorectal Cancer; MMRD: Mismatch Repair Deficiency; CRC: Colorectal Carcinoma; APC: Adenomatous Polyposis Coli gene; MHL-1 + MSH-2 ; UC: Ulcerative Colitis; NF1: Neurofibromatosis type 1; RMS: Rhabdomyosarcoma; MSI: Microsatellite Instability; CMMRD: Constitutional Mismatch Repair Deficiency; LMA: Acute Myeloid Leukemia; OS: Overall Survival ; NHL: Non Hodgkin Lymphoma; PFS: Progression-Free Survival; M1: Metastasis to distant organs; EFS: Event Free Survival.


CRC in children and adolescents has a strong association with inherited cancer susceptibility syndromes [1, 7, 9, 17, 21, 29]. In our series, we report 2 cases with previous diagnosis of inflammatory bowel disease (1 Crohn's disease and 1 ulcerative colitis), and 2 patients with previous diagnosis of High-grade glioma, one of them with Neurofibromatosis type 1.

Conclusion

CRC poses many challenges to pediatric oncologists because of the low incidence, the delay in diagnosis may substantially contribute to the poorer prognosis, added to the higher prevalence of worse prognosis factors. Also, there is a strong association with hereditary cancer predisposition syndromes such Lynch Syndrome or Familial adenomatous polyposis, with manifestations that, even when mostly appear in adults, the adequate early screening allows its prevention and timely treatment. Added to that, it is important for the pediatrician and the pediatric oncologist to be able to provide genetic counseling for all the family.

Conflicts of Interest

None.

Article Info

Article Type
Case Series and Review of the Literature
Publication history
Received: Fri 22, Jul 2022
Accepted: Mon 15, Aug 2022
Published: Mon 12, Sep 2022
Copyright
© 2023 Mathey Marina. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Hosting by Science Repository.
DOI: 10.31487/j.SCR.2022.09.01

Author Info

Corresponding Author
Mathey Marina
Department of Hematology and Oncology, Hospital de Pediatría S.A.M.I.C. “Prof. Dr. Juan P. Garrahan”, Buenos Aires, Argentina

Figures & Tables

Table 1: Case reports.



Age

Sex

Predisposing factors

Signs & Symptoms

Delay

Location

Histology

Dukes stage

Survival

1

11y10m

M

Ulcerative colitis

Ulcerative colitis

Colonoscopy control

Sigmoid- Rectum

Mucinous

D

alive

2

15y4m

M

-

Gastrointestinal bleeding

 + weight loss

3m

Sigmoid- Rectum

Mucinous + Signet-ring cells

C

Dead (OS 19.9m)

3

15y7m

F

-

Diarrhea + weight loss

2m

Hepato-colic angle

Mucinous

D

Dead (OS 6.2m)

4

13y11m

M

NF1 -High grade glioma

Abdominal pain + gastrointestinal bleeding

1.5m

Sigmoid

Mucinous

D

Dead

5

14y10m

M

-

-

-

Colon

Mucinous + Signet-ring cells

D

Dead (OS 11.3m)

6

15y5m

M

-

Abdominal pain + rectal bleeding + diarrhea + weight loss

4m

Rectum

Mucinous

-

Dead (OS 5.3m)

7

14y7m

F

-

Abdominal pain + anemia + weight loss

5m

Sigmoid- Rectum

Poorly differentiated

D

Dead (OS 7.9m)

8

19y

M

High grade glioma / glioblastoma

Lower gastrointestinal bleeding

-

-

 

-

-

Dead

9

17y

F

Crohn's disease

Crohn's disease

Colonoscopy control

Rectum

Well -differentiated

A

Dead (OS 10.3m)

10

16y

F

-

Acute surgical abdomen (occlusion) + anemia

8d

Hepatic flexure

Moderately differentiated

C

Dead (OS 18.5m)

11

14y9m

F

-

Acute surgical abdomen (pain + vomiting)

11d

Cecum

Signet-ring cells

D

Dead (OS 5.8m)

12

11y9m

M

-

Abdominal pain + change in bowel habits

3m

Sigmoid

Mucinous + Signet-ring cells

-

Dead

13

12y3m

M

-

Acute surgical abdomen + abdominal pain

3 m

Sigmoid

Signet-ring cells

-

Dead (OS 1.7m)

14

14y8m

M

-

Abdominal pain + weight loss + intestinal obstruction

3 m

Transverse

Mucinous

C

Dead

15

14y

M

-

Abdominal pain + vomiting + change in bowel habits

1m

Hepatic flexure

Moderately differentiated

C

Alive

y: Years; m: Months; d: Days; M: Male; F: Female; NF1: Neurofibromatosis type 1; OS: Overall Survival.


Table 2: Systematic literature review of case reports.

Author

n

Age (y)

Family History of CRC or Genetic Syndromes

Pathology

Stage

Survival/ Comments

Mathey, 2021, Argentina

15

< 20 (r:11-19)

2 history of HGG (1 NF1)

1 Crohn

1 UC

Mucinous: 9

Signet-ring cells: 5

Poorly differentiated: 6

Dukes C/D: 14

M1: 9

2 pts alive

Cortez-Pinto, 2019, Portugal [29]

5

< 18 (r:9-17)



4/5 had family history of cancer in 2nd-degree relatives (2 CRC history) No MSI or MMRD

3/5 signet ring cells/mucinous histology





Khan SA, 2016, USA [7]

94

<30

(r:11-30)

Family history in 43% (vs. 26% in adults)

Poorly differentiated 37%

Signet-ring cells 13%

Advanced stages 76%



OS 5-y 40-48% (vs. 70-81%) compared with adults

Poles GC, 2015, USA [16]

918

(SEER)

<21

FAP 2.6% (p<0.001) compared with adults

Signet-ring cells 15.4%

Mucinous 17.5%

Poorly differentiated 30%

Stages III-IV 62% (vs. 37%)



Weber ML, 2016, German [17]

31

≤18

11 pts: 8 HNPCC - 1 FAP - 2 other





OS 100% vs 36-50% without Genetic Syndromes

6 pts developed other malignancies: 3 NHL-T, 3 Glioblastoma

Du F, 2015,

China [8]

19

10-20

MMRD in 2 of 9 pts analyzed

Signet-ring cells 37%

Mucinous 26%

Stages: III 52.6% y IV 26.3%. Nodes + 89%.

OS 5-y 23%

Rahman M, 2014, Bangladesh [18]

7

6-10

2 FAP

2 Signet-ring cells

5 Poorly differentiated

Dukes Stages: 4 pts D, 1 pt By 2 pts A (both with FAP)



Kaplan MA, 2013, Turkey [1]

76



<25

15 family history of CRC (21.7%)

5 (6.8%) APC





OS 16.3 m (r: 1-107 m).

Tay CH, 2012, Taiwan [19]

8

0-18

-



87.5% Dukes stages C/D

25% CEA high level.

Sultan I, 2010, Jordan, SEER [2]

159

4-20

10% APC

Mucinous 22%.

Signet-ring cells 18%.

Poorly differentiated / undifferentiated 31.9%.

Localized 19%

OS 5-y 40% vs 60% adults

Salas-Valverde S, 2009, Costa Rica [13]

11

7-17

2 APC, 1 Turner syndrome

Mucinous 64%



0 Dukes A and 2 Dukes B: alive

9 Dukes C/D: OS: < 17 m

Delay in diagnosis: 6 days -1 y (media: 3.9 m).

Ferrari A, 2008, Italy [9]

27

<30

3 pts MSI (1 family history of HNPCC) vs.

6 FAP + 5 HNPCC in adults



Stages III-IV 86% vs 40% in adults

Delay in diagnosis: 1-12 m.

PFS 5-y 18% and OS 5-y 23% vs. PFS 62.5% and OS 73% in adults.

Hill DA, 2007, USA

[3]

77

7-19

1 FAP, 6 juvenile polyps,

1 UC, 1 NF1,

 2 history of irradiation because of RMS.

3 pts 2nd malignancy

Mucinous 62%

Advanced stages 86%, M1 51%.

OS 10-y: 20.1%; EFS 10-y: 17.7%.

21% pts alive with medial survival of 12.2 y.

Kravarusic D, 2007, Israel [20]

7

2-18

-

4 Mucinous +/- Signet-ring cells



Delay in diagnosis 2-12m

3 pts alive



Durno C, 2005, Canada [21]

16

9-24

8/11 MSI

6/14 CMMRD

1 CMMRD: homozygous MLH-1 - brother (11y) with duodenal adenocarcinoma





7/16 developed 2nd malignancies

Chantada GL, 2005, Argentina [5]

21

10-30

3 family history of CRC



Pts <20 years old: Staged III and IV

11/14 died

OS 5-y 10% vs. 72% in adults

Delay in diagnosis: 2-24 m

Radhakrisshnan CN, 2003, England [22]

8

<16

-

Poorly differentiated 50%

All Dukes stage C

All died (1-12 m from diagnosis)

Vastyan AM, 2001, Hungary / UK [14]

7

<15

(r:9-15)

1: 2nd malignancy (Astrocytoma previous)

 1: later presented 2nd malignancy (AML)

5/7 aggressive histological

5 Dukes stage C

2 Dukes stage D

*1 case: metastasis in ovaries (Kruckenberg tumors)

6 pts died (6m-5y from diagnosis)

Delay in diagnosis: 1-12 m (media 4 m)

Datta RV, 2000, USA [11]/

 La Quardia MP, 1992, USA [10].

29

<21

7 family histories of CRC

1 HNPCC

1 FAP

1 UC

6/16 MSI

1 previous irradiation because of Wilms´ tumor

Signet-ring cells 45%. Poorly differentiated 24%.



76%: lymph node involvement

24 % metastasis.



Median delay in diagnosis: 2 m

OS 3-y: 24%.

Median OS: 16 m

If complete resection: median OS 33 m

Karnak I, 1999, Turkey [23]

20

<16

(r:7-16)

3 family histories of CRC

1 Bloom Syndrome

16/20 (80%) Mucinous



100% advanced stage (35% Dukes C, 65% Dukes D)

17/20 died

Delay in diagnosis: 2-15 days in Acute surgical abdomen; 1-24m in other clinical presentations.

Steinberg, 1988, USA [24]

9

10-20

1 Turcot syndrome

6 Poorly differentiated or Mucinous





5 pts delayed diagnosis (>3 m, median delay in diagnosis 11,6 m): 2 pts Dukes C and 3 pts Dukes D, median OS 4 m.

4 pts early diagnosis (median 20 days): 3 Dukes C and 1 Dukes D, median OS 24 m.

Andersson, 1976, Sweden [25]

6

< 15

-





2 pts Acute surgical abdomen

All died. Longest survival 3y9m

Chabalco, 1975, USA [26]

76

<20

1 family CRC

4 FAP- 3 UC - 1 colitis granulomatous

1: Mangioendothelioma

1: Astrocytoma previous (Turcot syndrome)

32% Mucinous.





Brown, 1992, South Africa [15]

7

10-15

-

5 Mucinous

4 Poorly differentiated

2 Signet-ring cells.



4 pts initial diagnosis: Acute surgical abdomen

Delay in diagnosis 4.5m (r:2-6 m).

Lamego CMB, 1989, Brazil [27]

11

6-15

1 FAP

8 pts Mucinous

7 pts stages III and IV.

5 pts metastasis

Delay in diagnosis: 2-360 days

Goldthorn JF, 1983, Taiwan [28]

7

11-20

3 pts with predisposition (FAP o UC)

1 Mucinous

3 pts Dukes stage D

5 pts died

Indini, 2017, Italy [12]

12

< 18

2 pts MMRD.

5 Poorly differentiated

4 Mucinous

2 pts Signet-ring cells

All stages II/IV

6 pts metastasis.

6 pts alive with survival of 51.7 m

6 pts disease progression

OS of 17 m (r:3-34 m)

Delay in diagnosis: 1-12 m

Pts: Patients; y: Years; m: Months; HGG: High Grade Glioma; FAP: Familial Adenomatous Polyposis; HNPCC: Hereditary Non-Polyposis Colorectal Cancer; MMRD: Mismatch Repair Deficiency; CRC: Colorectal Carcinoma; APC: Adenomatous Polyposis Coli gene; MHL-1 + MSH-2 ; UC: Ulcerative Colitis; NF1: Neurofibromatosis type 1; RMS: Rhabdomyosarcoma; MSI: Microsatellite Instability; CMMRD: Constitutional Mismatch Repair Deficiency; LMA: Acute Myeloid Leukemia; OS: Overall Survival ; NHL: Non Hodgkin Lymphoma; PFS: Progression-Free Survival; M1: Metastasis to distant organs; EFS: Event Free Survival.


References

1.     Kaplan MA, Isikdogan A, Gumus M, Arslan UY, Geredeli C et al. (2013) Childhood, adolescents, and young adults (≤25 y) colorectal cancer: study of Anatolian Society of Medical Oncology. J Pediatr Hematol Oncol 35: 83-89. [Crossref]

2.     Sultan I, Rodriguez Galindo C, El Taani H, Pastore G, Casanova M et al. (2010) Distinct features of colorectal cancer in children and adolescents: a population-based study of 159 cases. Cancer 116: 758-765. [Crossref]

3.     Hill DA, Furman WL, Billups CA, Riedley SE, Cain AM et al. (2007) Colorectal carcinoma in childhood and adolescence: a clinicopathologic review. J Clin Oncol 25: 5808-5814. [Crossref]

4.     Ferrari A (2012) Intestinal Carcinomas. In: Schneider D.T., Brecht I.B., Olson T.A., and Ferrari A. (eds): Rare tumors in children and adolescents, Ed. Springer-Verlag Berlin Heidelberg 269-276.

5.     Chantada GL, Perelli VB, Lombardi MG, Amaral D, Cascallar D et al. (2005) Colorectal carcinoma in children, adolescents, and young adults. J Pediatr Hematol Oncol 27: 39-41. [Crossref]

6.     Kern WH, White WC (1958) Adenocarcinoma of the colon in a 9-month-old infant; report of a case. Cancer 11: 855-857. [Crossref]

7.     Khan SA, Morris M, Idrees K, Gimbel MI, Rosenberg S et al. (2016) Colorectal cancer in the very young: a comparative study of tumor markers, pathology and survival in early onset and adult onset patients. J Pediatr Surg 51: 1812-1817. [Crossref]

8.     Du F, Shi SS, Sun YK, Wang JW, Chi Y (2015) Clinicopathological Characteristics and Prognosis of Colorectal Cancer in Chinese Adolescent Patients. Chin Med J (Engl) 128: 3149-3152. [Crossref]

9.     Ferrari A, Rognone A, Casanova M, Zaffignani E, Piva L et al. (2008) Colorectal carcinoma in children and adolescents: the experience of the Istituto Nazionale Tumori of Milan, Italy. Pediatr Blood Cancer 50: 588-593. [Crossref]

10.  LaQuaglia MP, Heller G, Filippa DA, Karasakalides A, Vlamis V et al. (1992) Prognostic factors and outcome in patients 21 years and under with colorectal carcinoma. J Pediatr Surg 27: 1085-1090. [Crossref]

11.  Datta RV, LaQuaglia MP, Paty PB (2000) Genetic and phenotypic correlates of colorectal cancer in young patients. N Engl J Med 342: 137-138. [Crossref]

12.  Indini A, Bisogno G, Cecchetto G, Vitellaro M, Signoroni S et al. (2017) Gastrointestinal tract carcinoma in pediatric and adolescent age: The Italian TREP project experience. Pediatr Blood Cancer 64. [Crossref]

13.  Salas Valverde S, Lizano A, Gamboa Y, Vega S, Barrantes M et al. (2009) Colon carcinoma in children and adolescents: prognostic factors and outcome-a review of 11 cases. Pediatr Surg Int 25: 1073-1076. [Crossref]

14.  Vastyan AM, Walker J, Pintér AB, Gerrard M, Kajtar P (2001) Colorectal carcinoma in children and adolescents--a report of seven cases. Eur J Pediatr Surg 11: 338-341. [Crossref]

15.  Brown RA, Rode H, Millar AJ, Sinclair Smith C, Cywes S (1992) Colorectal carcinoma in children. J Pediatr Surg 27: 919-921. [Crossref]

16.  Poles GC, Clark DE, Mayo SW, Beierle EA, Goldfarb M et al. (2016) Colorectal carcinoma in pediatric patients: A comparison with adult tumors, treatment and outcomes from the National Cancer Database. J Pediatr Surg 51: 1061-1066. [Crossref]

17.  Weber ML, Schneider DT, Offenmüller S, Kaatsch P, Einsiedel HG et al. (2016) Pediatric Colorectal Carcinoma is Associated with Excellent Outcome in the Context of Cancer Predisposition Syndromes. Pediatr Blood Cancer 63: 611-617. [Crossref]

18.  Rahman MA, Chowdhury TK, Bhuiyan MA, Al Farooq MA, Sajid MM et al. (2014) Colorectal carcinoma in first decade of life: our experience. Pediatr Surg Int 30: 847-851. [Crossref]

19.  Tay CH, Lee HC, Yeung CY, Chan WT, Jiang CB et al. (2012) Different clinical manifestations between primary gastrointestinal malignancies and benign tumors in children. J Pediatr Gastroenterol Nutr 55: 440-444. [Crossref]

20.  Kravarusic D, Feigin E, Dlugy E, Steinberg R, Baazov A et al. (2007) Colorectal carcinoma in childhood: a retrospective multicenter study. J Pediatr Gastroenterol Nutr 44: 209-211. [Crossref]

21.  Durno C, Aronson M, Bapat B, Cohen Z, Gallinger S (2005) Family history and molecular features of children, adolescents, and young adults with colorectal carcinoma. Gut 54: 1146-1150. [Crossref]

22.  Radhakrishnan CN, Bruce J (2003) Colorectal cancers in children without any predisposing factors. A report of eight cases and review of the literature. Eur J Pediatr Surg 13: 66-68. [Crossref]

23.  Karnak I, Ciftci AO, Senocak ME, Büyükpamukçu N (1999) Colorectal carcinoma in children. J Pediatr Surg 34: 1499-1504. [Crossref]

24.  Steinberg JB, Tuggle DW, Postier RG (1988) Adenocarcinoma of the colon in adolescents. Am J Surg 156: 460-462. [Crossref]

25.  Andersson A, Bergdahl L (1976) Carcinoma of the colon in children: a report of six new cases and a review of the literature. J Pediatr Surg 11: 967-971. [Crossref]

26.  Chabalko JJ, Fraumeni JF Jr (1975) Colorectal cancer in children: epidemiologic aspects. Dis Colon Rectum 18: 1-3. [Crossref]

27.  Lamego CM, Torloni H (1989) Colorectal adenocarcinoma in childhood and adolescent. Report of 11 cases and review of the literature. Pediatr Radiol 19: 504-508. [Crossref]

28.  Goldthorn JF, Powars D, Hays DM (1983) Adenocarcinoma of the colon and rectum in the adolescent. Surgery 93: 409-414. [Crossref]

29.  Cortez Pinto J, Claro I, Francisco I, Lage P, Filipe B et al. (2021) Pediatric Colorectal Cancer: A Heterogenous Entity. J Pediatr Hematol Oncol 42: 131-135. [Crossref]

30. Mathey MD, Pennella CL, Zubizarreta P (2021) Colorectal carcinoma in children and adolescents. Arch Argent Pediatr 119: e487-e498. [Crossref]